Assembly Biosciences (NASDAQ:ASMB) Posts Earnings Results, Misses Estimates By $0.27 EPS

Assembly Biosciences (NASDAQ:ASMB) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.27), FiscalAI reports. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The business had revenue of $2.96 million during the quarter, compared to analyst estimates of $9.07 million.

Assembly Biosciences Price Performance

Shares of ASMB traded down $2.19 during trading hours on Thursday, hitting $20.18. The stock had a trading volume of 499,584 shares, compared to its average volume of 195,617. The firm has a 50 day simple moving average of $23.88 and a 200-day simple moving average of $26.91. The firm has a market capitalization of $410.88 million, a P/E ratio of 19.78 and a beta of 1.26. Assembly Biosciences has a 1-year low of $19.20 and a 1-year high of $39.71.

Insider Activity at Assembly Biosciences

In other Assembly Biosciences news, insider Nicole S. White sold 2,593 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $19.62, for a total value of $50,874.66. Following the completion of the sale, the insider owned 59,257 shares of the company’s stock, valued at approximately $1,162,622.34. This trade represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason A. Okazaki sold 6,202 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $19.62, for a total value of $121,683.24. Following the sale, the chief executive officer owned 195,532 shares of the company’s stock, valued at approximately $3,836,337.84. This represents a 3.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 12,115 shares of company stock valued at $237,696 in the last three months. Corporate insiders own 3.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on ASMB. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Thursday, October 15th. UBS Group dropped their price target on Assembly Biosciences from $52.00 to $48.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. Zacks Research downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Finally, Mizuho set a $53.00 target price on shares of Assembly Biosciences in a research report on Tuesday, September 1st. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Assembly Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $46.50.

About Assembly Biosciences

Assembly Biosciences is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus. The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.